Sign in
WithdrawnPhase 2

FMT for Remission of Active Ulcerative Colitis in Adults

Key facts

Who runs it
University of British Columbia
Where
Canada3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Mar 2022
Expected to end
Dec 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • FMT oral
  • FMT enema
  • Placebo oral
  • Placebo enema
Record updated
10 May 2023
Why it stopped
Protocol changed substantially enough to warrant a separate submission

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Able to provide informed consent
  • Willing and able to comply with all the required trial procedures
  • Active ulcerative colitis as defined by Mayo score > 3 AND Mayo endoscopic sub-score > 1 (within 30 days before enrollment, or at baseline)

Who cannot take part

  • Planned or actively taking another investigational product
  • Abdominal surgery within the past 60 days
  • Increase in medical therapy for UC within 3 months of enrollment. Continued treatment with stable dose of 5-ASA, azathioprine, 6-mercaptopurine, cyclosporine, prednisone and/or anti- TNF agents for at least 3 months of is allowed
  • Requiring oral and/or intravenous systemic antibiotic therapy at the time of study enrolment
  • History of anaphylaxis to any food
  • Severe underlying disease such that the patient is not expected to survive for at least 30 days
  • Any condition that in the opinion of the investigator that would pose harm to the participant or the research staff for the potential participant to take part in the trial
  • Patients with neutropenia with absolute neutrophil count <0.5 x 109/L at - Evidence of toxic megacolon or gastrointestinal perforation on imaging
  • Peripheral white blood cell count > 35.0 x 109/L at enrollment AND temperature > 38.0oC
  • Active infectious diarrhea at the time of enrolment
  • Severe UC requiring hospitalization at the time of enrolment
  • Pregnant or lactating
  • Unwilling to discontinue probiotic (yogurt is allowed)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to establish the safety and effectiveness of lyophilized (LYO) fecal microbiota transplant (FMT) for treating ulcerative colitis (UC) in adults. The protocol is being re-designed to address relevant, current research questions in the context of FMT treatment for UC. Once a final protocol is approved, this webpage will be updated.

The 3 groups in the trial

  • Placebo oral & enemaPlacebo, for comparison

    twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema

    Treatment: Placebo oral and Placebo enema

  • LYO-FMT oral + placebo enemaExisting treatment, for comparison

    twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema

    Treatment: FMT oral and Placebo enema

  • LYO-FMT oral + LYO-FMT enemaExisting treatment, for comparison

    twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema

    Treatment: FMT oral and FMT enema

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Double-blind, Placebo-controlled Trial of Lyophilized Fecal Microbiota Transplantation for the Induction of Remission in Adults With Active Ulcerative Colitis
Record updated
10 May 2023